Cardiovascular Disease Solutions

Challenging the HFpEF Treatment Dogma

The landmark myPACE trial found that patients with HFpEF who have their pacemakers’ set to a higher backup resting heart rate reaped important health benefits. The findings challenge the long-standing belief among cardiologists that patients with HFpEF and diastolic dysfunction benefit from lower heart rates.  

The authors screened 1,500 patients with HFpEF and randomly assigned 107 of them to receive either standard pacing at 60 bpm or a higher rate based on age, height, and ejection fraction. The screening process was so selective because they only included those with existing pacemakers that allowed the researchers to increase the heart rate without exacerbating RV dyssynchrony. 

At one year, the personalized accelerated pacing led to improvements in… 

  • NT-proBNP levels (-109 pg/dL vs. +128 pg/dL) 
  • Physical activity levels (+47 minutes/day vs. -22 minutes/day)
  • AFib (27% relative risk reduction) 

The Takeaway
The study rewrites the long-held view that lower pacing is better for people with HFpEF. Of course, this is just one, small RCT, and larger scale studies are necessary to confirm the findings. Interestingly, the findings do align with a 2021 study that found that beta blocker withdrawal in HFpEF patients improved maximal functional capacity.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!